J Med Microbiol Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vuopio-Varkila, J.
Right arrow Articles by Makela, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vuopio-Varkila, J.
Right arrow Articles by Makela, P. H.
Agricola
Right arrow Articles by Vuopio-Varkila, J.
Right arrow Articles by Makela, P. H.

The Journal of Medical Microbiology, Vol 25, Issue 3 197-203, Copyright © 1988 by Society for General Microbiology

JOURNAL ARTICLE

Lipopolysaccharide-induced non-specific resistance to systemic Escherichia coli infection in mice

J. Vuopio-Varkila, M. Nurminen, L. Pyhala and P. H. Makela
National Public Health Institute, Helsinki, Finland.

A high degree of non-specific resistance to a lethal systemic Escherichia coli infection was induced in mice by pretreatment with a small dose (less than 5 micrograms/mouse) of the homologous lipopolysaccharide (LPS) or with heterologous rough-type LPS from E. coli K-12. The route of LPS administration, intraperitoneally or subcutaneously, did not influence the development of resistance, suggesting that a systemic cell activation was responsible for the effect. The enhanced elimination of bacteria was similar to that in mice recovering from a sublethal E. coli infection. In the LPS-treated mice, elimination of the challenge bacteria from the peritoneal cavity and the blood started 3-4 h after challenge whereas, in controls, the bacterial numbers continued to increase until the mice died. The detoxified LPS derivative, monophosphoryl lipid A (MPL), also increased the survival of mice infected with E. coli O18:K1. However, the dose of MPL required for optimal infection resistance was 100-fold greater than that of native, E. coli K-12 LPS, corresponding to the 100-fold reduced toxicity of MPL for mice and rabbits in lethality and pyrogenicity assays.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
K. Okemoto, K. Kawasaki, K. Hanada, M. Miura, and M. Nishijima
A Potent Adjuvant Monophosphoryl Lipid A Triggers Various Immune Responses, but Not Secretion of IL-1{beta} or Activation of Caspase-1
J. Immunol., January 15, 2006; 176(2): 1203 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
E. A. M. van Rijen, J. J. Ward, and R. A. Little
Effects of Colloidal Resuscitation Fluids on Reticuloendothelial Function and Resistance to Infection after Hemorrhage
Clin. Vaccine Immunol., July 1, 1998; 5(4): 543 - 549.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL J MED MICROBIOL MICROBIOLOGY J GEN VIROL ALL SGM JOURNALS
Copyright © 1988 Society for General Microbiology.